- 関
- DLT
WordNet
- travel or traverse (a distance); "This car does 150 miles per hour"; "We did 6 miles on our hike every day"
- the syllable naming the first (tonic) note of any major scale in solmization (同)doh, ut
- proceed or get along; "How is she doing in her new job?"; "How are you making out in graduate school?"; "Hes come a long way" (同)fare, make_out, come, get along
- create or design, often in a certain way; "Do my room in blue"; "I did this piece in wood to express my love for the forest" (同)make
- carry on or function; "We could do with a little more help around here" (同)manage
- get (something) done; "I did my job" (同)perform
- treat with an agent; add (an agent) to; "The ray dosed the paint"
- the quantity of an active agent (substance or radiation) taken in or absorbed at any one time (同)dosage
- a measured portion of medicine taken at any one time (同)dosage
- strictly limiting the reference of a modified word or phrase; "the restrictive clause in `Each made a list of the books that had influenced him limits the books on the list to only those particular ones defined by the clause"
- the degree to which something is poisonous
- treated with some kind of application; "a mustache dosed with bear grease"
PrepTutorEJDIC
- 《疑問文・否定文を作る》 / 《否定命令文を作る》 / 《助動詞とbe動詞のどちらも含まない文に用いて付加疑問を作る》 / 《強意語として》 / 《文》《助動詞とbe動詞のどちらも含まない文に用いて倒置文を作る》 / 《あいづちを打つ場合に》 / 《先行する動詞またはそれを含む述部の代用》 / 《so,nor,neitherで始まる簡略文で》 / …‘を'『する』,行う,果たす / 《通例have done,時にbe doneの形で》…‘を'『終える』,済ませる / …‘を'作る,作り出す / …‘を'『処理する』,整える,片付ける / 〈学課〉‘を'『勉強する』,専攻する / 〈利益・害など〉‘を'与える,もたらす / 〈人〉‘に'『役立つ』,用が足りる(serve) / …の速度で進む,距離を行く / …‘を'見物する / 〈劇〉‘を'上演する;…‘の'役を演じる / …の役目(仕事)をする / 《おもに英》…‘を'だます,かつぐ / 《話》…をへとへとにさせる / 『する』;活動する / 《通例have done,時にbe doneの形で》(…を)『終える』,済ます《+『with』+『名』》 / 〈事が〉『運ぶ』;〈人が〉暮らしていく,健康である / 〈物が〉(…に)『間に合う』,十分である;〈人が〉(…に)役に立つ,向く《+『for』+『名』》 / 《複数形で》すべきこと / 〈C〉《おもに英》大宴会,大パーティー / 〈C〉《英話》詐欺,ぺてん
- ド(全音階の第1音)
- (おもに飲み薬1回分の)『服用量』 / (痛いこと・いやなことの)1回分,一定量 / (人などが受ける放射線の)線量 / 性病 / (…を)…‘に'投薬する,服用させる《+『名』+『with』+『名』》
- 制限する,限定する
- 毒性,有毒性
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 低用量メトトレキサートの主な副作用 major side effects of low dose methotrexate
- 2. 炎症性疾患におけるシクロホスファミドおよびクロラムブシルの全身毒性 general toxicity of cyclophosphamide and chlorambucil in inflammatory diseases
- 3. 肝疾患を有する患者における化学療法による肝毒性および用量調整 chemotherapy hepatotoxicity and dose modification in patients with liver disease
- 4. 化学療法関連腎毒性および腎不全患者における用量調整 chemotherapy related nephrotoxicity and dose modification in patients with renal insufficiency
- 5. 高用量メトトレキサートの治療使用および毒性 therapeutic use and toxicity of high dose methotrexate
English Journal
- Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
- Canter RJ1, Borys D, Olusanya A, Li CS, Lee LY, Boutin RD, Christensen SD, Tamurian RM, Monjazeb AM.Author information 1Division of Surgical Oncology, UC Davis Comprehensive Cancer Center, University of California Davis Medical Center, Sacramento, CA, USA, Robert.canter@ucdmc.ucdavis.edu.AbstractBACKGROUND: Despite effective local therapy with surgery and radiotherapy (RT), ~50 % of patients with high-grade soft tissue sarcoma (STS) will relapse and die of disease. Since experimental data suggest a significant synergistic effect when antiangiogenic targeted therapies such as sorafenib are combined with RT, we chose to evaluate preoperative combined modality sorafenib and conformal RT in a phase I/II trial among patients with extremity STS amenable to treatment with curative intent.
- Annals of surgical oncology.Ann Surg Oncol.2014 May;21(5):1616-23. doi: 10.1245/s10434-014-3543-7. Epub 2014 Feb 20.
- BACKGROUND: Despite effective local therapy with surgery and radiotherapy (RT), ~50 % of patients with high-grade soft tissue sarcoma (STS) will relapse and die of disease. Since experimental data suggest a significant synergistic effect when antiangiogenic targeted therapies such as sorafenib are
- PMID 24554062
- Phase I trial of Cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
- Tsao AS1, Harun N2, Lee JJ2, Heymach J3, Pisters K3, Hong WK4, Fujimoto J5, Wistuba I5.Author information 1Department of Thoracic, Head, and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: astsao@mdanderson.org.2Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.3Department of Thoracic, Head, and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.4Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.5Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.AbstractBACKGROUND: We conducted a phase I trial of cisplatin/pemetrexed/imatinib mesylate, an oral platelet-derived growth factor receptor (PDGFR) inhibitor, in chemonaive patients with malignant pleural mesothelioma (MPM).
- Clinical lung cancer.Clin Lung Cancer.2014 May;15(3):197-201. doi: 10.1016/j.cllc.2013.12.008. Epub 2013 Dec 27.
- BACKGROUND: We conducted a phase I trial of cisplatin/pemetrexed/imatinib mesylate, an oral platelet-derived growth factor receptor (PDGFR) inhibitor, in chemonaive patients with malignant pleural mesothelioma (MPM).METHODS: A standard 3 + 3 dose-escalating trial was used with the end points of ma
- PMID 24492162
- Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
- Shimizu T1, Sonoda H2, Murata S2, Takebayashi K2, Ohta H2, Miyake T2, Mekata E2, Shiomi H2, Naka S2, Tani T2.Author information 1Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowacho, Otsu, Shiga 520-2192, Japan. Electronic address: tomoharu@belle.shiga-med.ac.jp.2Department of Surgery, Shiga University of Medical Science, Seta-Tsukinowacho, Otsu, Shiga 520-2192, Japan.AbstractINTRODUCTION: The drugs and protocols used for hyperthermic intraperitoneal chemotherapy (HIPEC) vary among institutions. Here we show the efficacy of the 3-drug combination of mitomycin C (MMC), 5-fluorouracil (5FU), and oxaliplatin (OHP) in an in vitro simulation of HIPEC and the safety of HIPEC with these drugs during a Phase I study of patients at high risk of developing colorectal peritoneal metastasis.
- European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.Eur J Surg Oncol.2014 May;40(5):521-8. doi: 10.1016/j.ejso.2013.12.005. Epub 2013 Dec 18.
- INTRODUCTION: The drugs and protocols used for hyperthermic intraperitoneal chemotherapy (HIPEC) vary among institutions. Here we show the efficacy of the 3-drug combination of mitomycin C (MMC), 5-fluorouracil (5FU), and oxaliplatin (OHP) in an in vitro simulation of HIPEC and the safety of HIPEC
- PMID 24388411
Japanese Journal
- Effect of 5-Fluorouracil Treatment on SN-38 Absorption from Intestine in Rats
- Shibayama Yoshihiko,Iwashita Yoshitaka,Yoshikawa Yoshimi [他]
- Biological & Pharmaceutical Bulletin 34(9), 1418-1425, 2011-09
- … 5-Fluorouracil (5-FU)-based chemotherapies with irinotecan have been applied for the treatment of cancers, and a common dose-limiting toxicity is neutropenia and diarrhea. …
- NAID 40018970948
- 臨床研究 再発・難治性T細胞性急性リンパ性白血病およびT細胞性リンパ芽球性リンパ腫に対するネララビンの第1相試験
- 堀部 敬三,瀧本 哲也,横澤 敏也 [他]
- 臨床血液 52(6), 406-415, 2011-06
- NAID 40018898427
Related Links
- び用量制限毒性（DLT: dose-limiting toxicity）. 用量制限毒性（種類、程度及びその 頻度）や最大耐量、又は最大許容量等の定義とそ. の判断規則についてあらかじめ明確 に規定しておくこと。 ・薬物動態（PK）及び薬物動態/薬力学（PK/PD）の評価. ・腫瘍縮小 ...
- 用量規定毒性: 「DLT (dose limiting toxicity)」参照。 予期せぬ副作用: 「予期せぬ」とは 、治験薬概要書あるいは実施計画書に記載されていないこと。予期せぬ副作用は、治験 薬概要書あるいは実施計画書に記載されていない副作用、もしくは記載事項と重篤 ...
Related Pictures
![Photo: Wikimedia Commons [1]](https://1mg.info/0/4/c/1105.jpg)
★リンクテーブル★
| リンク元 | 「DLT」「用量制限毒性」「用量規制毒性」「用量規定毒性」 |
| 関連記事 | 「do」「dose」「limiting」「dosing」「toxicity」 |
「DLT」
「用量制限毒性」
「用量規制毒性」
「用量規定毒性」
「do」
- v.
- する、行う
「dose」
- n.
「limiting」
- 極限の、律速の
「dosing」
- n.
「toxicity」